Draft agenda – subject to change

*All times are in EST


Fri 28

8:00AM -8:05AM

Welcome & Introductions
Meeting Chairs: Claire Harrison & Naveen Pemmaraju 

8:05AM -9:05AM

Session 1: Biology
Chairs: Ronald Hoffman & Claire Harrison

  • Calreticulin biology and targeting: Bethan Psaila
  • Genomics of MPN – Updates in 2024: Olatoyosi Odenike
  • Pathophysiology of progression: Ronald Hoffman
  • CHIP, JAK2 and MPN: David Steensma

Panel discussion

9:05AM -9:55AM

Session 2 PV and ET
Chairs: Andrew Kuykendall & Kristen Pettit

  • New options for the management of ET but do all patients need treatment: Kristen Pettit
  • Current data regarding young MPN patients: Lucia Masarova
  • Should we still use HU first line for PV patients? Andrew Kuykendall

Panel discussion

9:55AM -10:25AM


10:25AM -11:30AM

Session 3: Endpoint discussion in MPNs
Chairs: Ruben Mesa & Claire Harrison

  • Should SVR35 still be the gold standard in MF, and if not, what are the options?: John Mascarenhas
  • Is there a ceiling in assessing symptom response for MF/ MPNs?: Ruben Mesa
  • The future of clinical trials in MF: an industry perspective: David Steensma
  • Disease modification as an endpoint in PCV/ET: Jan Bewersdorf

Panel discussion

11:30AM -12:30PM

Session 4: CMML and BPDCN
Chairs: Michael Savona & John Bennett     

  • RASopathies, key features of RAS family-mutated CMML and treatment options: Mrinal Patnaik
  • The special case of MDS/MPN-RS-T: Valeria Santini
  • BPDCN: Naveen Pemmaraju
12:30PM -1:30PM


1:30PM -2:40PM

Session 5: Unmet needs in Myelofibrosis
Chairs: Naveen Pemmeraju & TBC

  • Important updates with combination therapy in MF in first line I: Pelabrasib: Claire Harrison
  • Important updates in frontline combo MF II: BCLxL: navitoclax & selinexor: Naveen Pemmaraju
  • New options for management of thrombocytopenia and anemia in MF: Aaron Gerds
  • Pre-fibrotic myelofibrosis: Abdulraheem Yacoub

Panel discussion

2:40PM -3:50PM

Session 6: Accelerated disease and transplant
Chairs: John Mascarenhas & David Steensma

  • How to define accelerated phase MPN: Lucia Masarova
  • Transplantation for MF in chronic and accelerated phase: Donal McLornan
  • Pathologist features of MPN in evolution: Mina Xu

Panel discussion


3:50PM -4:10PM


4:10PM -5:10PM

Session 7: Targeting the iron pathway from anemia to polycythemia
Chairs: Aaron Gerds & Donal McLornan

  • Utilizing momelotinib to treat anemia in MPN: Claire Harrison
  • Treating anemia in in MF with luspatercept: Aaron Gerds
  • Controlling erythrocytosis with rusfertide in PV: Ronald Hoffman
  • Clinical experience targeting hepcidin pathways in PV: Marina Kremyanskaya

Panel discussion

5:10PM -6:00PM

Session 8: Overlaps with MDS
Chairs: Claire Harrison & Daniel Wiseman

  • Targeting telomerase in MPN and MDS: John Mascarenhas
  • What should MPN learn from MDS?: Matteo Della Porta
  • Approaches from the MDS/MPN IWG: ABNL MARRO and beyond: Daniel Wiseman

Panel discussion

6:00PM -6:05PM

Conclusions & end of Day 1


Sat 29

8:00AM -8:10AM

Introduction & meeting objectives
Chair: Amer Zeidan

8:10AM -9:30AM

Session 1: New trends in CHIP/CCUS
Chairs: Michael Savona & Uma Borate

  • The SEARCH CONSORTIUM: Looking for Answers in CHIP And CCUS: Zhuoer Xie
  • Clonal hematopoiesis and transplantation outcomes: Coleman Lindsley
  • Should CCUS be considered as lower risk MDS?: Lachelle Weeks
  • Clonal hematopoiesis and bone marrow failure disorders; Austin Kulasekararaj
  • Putting it all together: Michael Savona

Panel discussion

9:30AM -9:50AM

Keynote talk:

Leveraging the icMDS combined database to answer timely and important questions on classification and risk stratification in MDS: Matteo Della Porta

9:50AM -10:10AM


10:10AM -11:50AM

Session 2: Rising STARs session: MDS in special populations
Chairs: Amer Zeidan & Stephen Nimer

  • DDX41-mut MDS/AML: Carmelo Gurnari
  • MDS in young patients: Yasmin Abaza
  • Cohesin genes mutated MDS: Tariq Kewan

Panel discussion

  • How to approach hypoplastic MDS: Emma Groarke
  • Targeting splicing mutation mutated in MDS: Jan Bewersdorf
  • How should TP53-mutated MDS be classified?: Bing Li
  • Should TPO Mimetics be standard of care In thrombocytopenic LR-MDS: Anne Sophie Kubasch

Panel discussion

11:50AM -1:10PM

Session 3: New directions and governmental progress
Chairs: Valeria Santini & Elizabeth Griffiths                                    

  • Oral hypomethylating agents in MDS – what is next?: Elizabeth Griffiths
  • Impact of responses to HMAs in context of baseline Genetic risk and Transplant: a VALIDATE icMDS analysis: Maximilian Stahl
  • Overview of the NIH Program for MDS: Alain Mina
  • Overview of CTEP/NCI efforts for MDS: Olatoyosi Odenike
  • Improving Governmental-Academic collaborations for better MDS research: Steven Gore

Panel discussion

1:10PM -2:10PM


2:10PM -3:20PM

Session 4: Inflammation and immune interventions
Chairs: Andrew Wei & Rena Buckstein                                                                                                  

  • IRAK inhibitors in MDS and AML: Uwe Platzbecker
  • STAT3 targeting in MDS: Aditi Shastri
  • Immune checkpoint use in MDS/AML-a dead end?: Amer Zeidan

Panel discussion

3:20PM -4:50PM

Session 5: Classification and risk stratification updates
Chairs: Maria Teresa Voso & Olatoyosi Odenike

  • Roadmap for harmonization of classifications: Somedeb Ball
  • Prognosis assessment in resource-limited countries: Maria Teresa Voso
  • Predicting relapse risk in MDS post-transplant: Ready for primetime?: Christopher Hourigan
  • The Role of Classification versus Prognostication in MDS Patients: Robert Hasserjian
  • Towards uniform and inclusive patient eligibility criteria for MDS clinical trials: Uma Borate

Panel discussion

4:50PM -5:10PM


5:10PM -6:00PM

Keynote talk – Proceedings from FDA/NCI workshop on drug development in MDS: Nina Kim
Chairs: Amer Zeidan & Michael Savona

Panel discussion – Kelly Norsworthy, David Steensma, Steven Gore, Valeria Santini

6:00PM -6:20PM

Recognition awards

6:20PM -6:30PM

Wrap up of Day 2


Sun 30

8:00AM -9:20AM

Session 6: Response assessment & regulatory considerations
Chairs: Amer Zeidan & Nina Kim  

  • How can we measure disease modification in LR-MDS: Rami Komrokji
  • How should MDS-IB2 (AML/MDS) be approached in clinic and trials? Katharina Götze
  • Do we still need to do bone marrow evaluations to diagnose, risk stratify and evaluate for response in MDS? Lisa Pleyer
  • MRD negative CR as an endpoint in MDS: Arjan van de Loosdrecht
  • IWG response criteria evolution for higher-risk MDS: Andrew Brunner

Panel discussion

9:20AM -10:20AM

Session 7: TP53 aberrations and Secondary AML
Chairs: Valeria Santini & Andrew Wei 

  • How to use TP53 status for clinical decisions in MDS?: Coleman Lindsley
  • Therapies for secondary AML: Thomas Cluzeau
  • Targeting the CD47-SIRPa axis in MDS/AML: David Sallman
  • Putting it together: current and future perspectives in TP53 mutated AML: Andrew Wei

Panel discussion

10:20AM -10:50AM


10:50AM -12:00PM

Session 8: Advances in LR-MDS therapies
Chairs: Uwe Platzbecker & Valeria Santini     

  • Telomerase inhibition: Uwe Platzbecker
  • TGF pathway modulation: Amer Zeidan
  • Is roxadustat and HIF targeting in MDS still a viable approach?: Valeria Santini
  • Putting it together – how do I manage LR-MDS in 2023: Hetty Carraway

Panel discussion

12:00PM -1:00PM


1:00PM -2:10PM

Session 9: Updates in HR-MDS therapies
Chairs: Andrew Wei & Amer Zeidan

  • IDH inhibitors- mono or combination therapy in MDS?: Marie Sebert
  • RARA agonists- Updates in use of RARA agonists in MDS?: Amy DeZern
  • Venetoclax in HR-MDS – SOC or not?: Yazan Madanat
  • Do selectin inhibitors have potential role in HR-MDS/AML?: Gail Roboz
  • Putting it all together – New directions in management of HR-MDS: Andrew Wei

Panel discussion

2:10PM -3:10PM

Session 10: Big data and quality of life measures
Chairs: Rena Buckstein & Mikkael Sekeres

  • Evolving role of artificial intelligence for MDS prognostication: Adrián Mosquera Orgueira
  • Clinical characteristics of MDS using registration data in Japan: Yasushi Miyazaki
  • QoL assessment in MDS in trials and clinical practice – the icMDS recommendations: Fabio Efficace
  • Using real world data and quality of life as meaningful enpoints in trials: Mikkael Sekeres

Panel discussion

End of meeting summary